Xinling Pharmaceuticals

Shaanxi Xinling Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company specializing in the research, development, and production of Traditional Chinese Medicine (TCM) and modern chemical drugs. The company focuses on therapeutic areas including cardiovascular, cerebrovascular, and respiratory diseases, addressing significant health needs in the domestic market. Its flagship product, Xinling Granules, is a widely recognized TCM formulation used for the treatment of coronary heart disease and angina pectoris by improving myocardial blood supply. Xinling operates state-of-the-art, GMP-certified manufacturing facilities that support the large-scale production of tablets, capsules, and granules. The company is committed to TCM modernization, utilizing advanced extraction and purification technologies to enhance the efficacy of natural products. Publicly listed on the National Equities Exchange and Quotations (NEEQ) in China, Xinling maintains a strong commercial presence through an extensive nationwide distribution network.